ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

24 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021

17 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference

15 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

13 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021

27 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®

27 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

20 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

09 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

26 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

12 Aug 2021 06:00:02 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021

05 Aug 2021 06:00:02 By Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

04 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia

28 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

24 Jun 2021 15:15:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces $50 Million Registered Direct Offering

22 Jun 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

21 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

14 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

08 Jun 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

03 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

26 May 2021 06:00:01 By Nasdaq GlobeNewswire